Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC

Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3 on T cells, has generated impressive treatment response rates in relapsed extensive-stage SCLC and large cell neuroendocrine carcinoma. We performed a retrospective, multi-institutional analysis of 48 patients who received...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Graeme Fenton, MD, Annie L. Zhang, MD, Sharon Zhong, PharmD, Curtis Tatsuoka, PhD, Michelle Sittig, RN, OCN, Alexandra Simms, PharmD, BCOP, Ranee Mehra, MD, Afshin Dowlati, MD, Taofeek K. Owonikoko, MD, PhD, Katherine Scilla, MD, Melinda Hsu, MD, Samuel Rosner, MD
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2026-04-01
سلاسل:	JTO Clinical and Research Reports
الموضوعات:	Small cell lung cancer Tarlatamab Bispecific antibody Real-world Survival analysis ctDNA
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666364325001511
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!